Members of the American Pharmacists Association Foundation’s Impact Care Transformation Network are gaining access to a point-of-care COVID-19 antibody test. The APhA Foundation is partnering with NowDiagnostics to make the company’s AdexusDx COVID-19 antibody test available to Impact Network members.
The AdexusDx test offers 15-minute results on the presence of COVID-19 antibodies using a self-contained fingerstick test. Impact Network member pharmacies will be able to offer the test to patients, with their results delivered via APhA Foundation’s RxTest.Solutions, a platform that enables secure patient and provider access to results.
"The APhA Foundation is pleased to offer the AdexusDx COVID-19 antibody test through our Impact Network pharmacies across the country in conjunction with RxTest.Solutions, and we know that pharmacists will use the test to continue to provide exceptional patient care,” said Benjamin Bluml, senior vice president of research and innovation at the APhA Foundation. “As has been demonstrated since the pandemic began, pharmacist-provided care is essential to the public health and wellbeing of communities everywhere, and we believe this opportunity with NOWDiagnostics and the APhA Foundation presents another excellent way for pharmacists to serve their patients and communities.
The AdexusDx test received emergency use authorization from the Food and Drug Administration in May for use in moderately complex settings and at the point of care. The company noted that antibody testing is crucial to identifying convalescent plasma donors who can provide therapy to COVID-19 patients. It is not yet known whether antibody presence confers immunity to infection from SARS-CoV-2.
“It is a privilege to partner with the APhA Foundation to offer an important COVID-19 test solution to our nation's pharmacists, one of the most trusted groups of healthcare professionals,” NowDiagnostics CEO Kevin Clark said. “We are grateful for the important work that pharmacists have been performing on the front lines, providing vaccines to prevent the spread of COVID-19. We are pleased to provide them with another important tool to ensure the health and safety of their patients.”